Regeneron to acquire rights for Hansoh’s HS-20094 therapy

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS-20094.

Jun 3, 2025 - 06:00
Regeneron to acquire rights for Hansoh’s HS-20094 therapy
Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS-20094.

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow